← Back to Search

AH-HA EHR Tool for Heart Health in Cancer Survivors (AH-HA Trial)

Waitlist Available
Led By Kathryn Weaver, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
>= 6 months post-potentially curative cancer treatment for breast, prostate, colorectal, or endometrial cancers or Hodgkin and non-Hodgkin lymphomas. Ongoing hormonal therapies such as tamoxifen, aromatase inhibitors (with or without adjuvant CDK 4/6 inhibitors such as abemaciclib), or androgen deprivation are allowed.
Scheduled for a routine cancer-related follow-up care visit within the next 30 days with a provider who received training to use AH-HA.
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

AH-HA Trial Summary

This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.

Who is the study for?
This trial is for adults over 18 who are cancer survivors (specifically of breast, prostate, colorectal, endometrial cancers or Hodgkin and non-Hodgkin lymphomas) with no current evidence of disease. They must understand English or Spanish, consent verbally to participate, be able to complete a follow-up in one year and have finished curative treatment at least 6 months ago.Check my eligibility
What is being tested?
The study tests an electronic health record tool called AH-HA designed to improve heart health discussions between patients and doctors. It will also look at whether the tool helps increase referrals to primary care/cardiology and promotes activities that reduce cardiovascular risk among cancer survivors.See study design
What are the potential side effects?
Since this intervention involves using a digital assessment tool rather than medication or medical procedures, traditional physical side effects are not expected. However, there may be indirect effects on healthcare practices.

AH-HA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
It's been over 6 months since my last cancer treatment, but I may still be on hormone therapy.
I have a cancer follow-up visit within 30 days with an AH-HA trained provider.
I am cancer-free except for non-melanoma skin conditions.
I am 18 years old or older.
I understand the study and agree to participate.

AH-HA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of patients reporting at least one non-ideal or missing CVH topic
Secondary outcome measures
CVH behaviors recorded in the past year
CVH factors recorded in the past year
Completed visits with primary care providers and cardiology
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

AH-HA Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention - AH-HA toolExperimental Treatment1 Intervention
With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.
Group II: Usual CareActive Control1 Intervention
Usual care practices will conduct routine follow-up care visits for enrolled survivors following typical clinic practice, without use of the AH-HA tool.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,570 Previous Clinical Trials
41,223,429 Total Patients Enrolled
559 Trials studying Prostate Cancer
506,278 Patients Enrolled for Prostate Cancer
University of Texas Southwestern Medical CenterOTHER
1,027 Previous Clinical Trials
1,044,426 Total Patients Enrolled
16 Trials studying Prostate Cancer
2,135 Patients Enrolled for Prostate Cancer
Washington University School of MedicineOTHER
1,918 Previous Clinical Trials
2,283,167 Total Patients Enrolled
18 Trials studying Prostate Cancer
4,271 Patients Enrolled for Prostate Cancer

Media Library

AH-HA Tool in the EPIC EHR Clinical Trial Eligibility Overview. Trial Name: NCT03935282 — N/A
Prostate Cancer Research Study Groups: Intervention - AH-HA tool, Usual Care
AH-HA Tool in the EPIC EHR 2023 Treatment Timeline for Medical Study. Trial Name: NCT03935282 — N/A
Prostate Cancer Clinical Trial 2023: AH-HA Tool in the EPIC EHR Highlights & Side Effects. Trial Name: NCT03935282 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots left in this research project?

"Clinicaltrials.gov affirms that this particular medical trial is no longer recruiting patients at the present time, having been initially listed on October 1st 2020 and most recently updated November 3rd 2022. However, 7027 other trials are actively searching for participants right now."

Answered by AI

How widespread is this medical trial across the state?

"11 prospective clinical trial centres are currently signing up patients. These sites span cities such as Saint Louis, Scranton and Appleton among 11 other locales. It is advised that you select the closest clinic to your location in order to reduce travelling requirements should you choose to join this study."

Answered by AI
~0 spots leftby Mar 2024